| 08.17.23 | Abcuro corrals $155M to advance KLRG1 med; Selecta silos gout drug, halts other work

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

1 jahr vor

Html
Text


A message from Fierce Biotech Summit

Today’s Big News

Aug 17, 2023

Sanofi-backed Abcuro loads up with $155M series B to push KLRG1 antibody through clinic

Selecta narrows focus to gout drug, freezing rest of pipeline

UK biotech founded by Nobel laureate rides the SPAC track out of the graveyard

Novo Holdings backs Sangon Biotech in $290M financing round

Erasing epigenetic 'memory' to improve the quality of stem cells


A message from Medical Affairs Strategic Summit

Featured

Sanofi-backed Abcuro loads up with $155M series B to push KLRG1 antibody through clinic

By James Waldron

Abcuro will draw on an oversubscribed series B round to continue the journey of its anti-KLRG1 candidate through clinical trials for a muscle disease and cancers.

11-14Sep

Join us: Digital Pharma EastPhiladelphia, PA

Selecta narrows focus to gout drug, freezing rest of pipeline

By James Waldron

Three months after laying off a quarter of its workforce, Selecta Biosciences is now halting investment in all but one of its non-partnered programs to eke out enough cash into 2027.

UK biotech founded by Nobel laureate rides the SPAC track out of the graveyard

By Max Bayer

The last clinical update from Celixir came more than three years ago just as the COVID-19 pandemic was upending ongoing trials. Now, a newly-formed SPAC has plucked the company out of the biotech graveyard.

Novo Holdings backs Sangon Biotech in $290M financing round

By Gabrielle Masson

Global life science investor Novo Holdings is backing research product provider Sangon Biotech in a $290 million financing that will help the China-based company diversify its portfolio and expand internationally.


A message from Digital Pharma East

Erasing epigenetic 'memory' to improve the quality of stem cells

By Helen Floersh

Progress in regenerative medicine has been hampered in part by the fact that while the resulting induced pluripotent stem cells, or iPS cells, are very similar to natural stem cells, their genomes still carry the biological “memories” of the cells from which they were derived. Now, researchers have found a way to make that transformation more thorough.

Parexel picks pact with Partex to leverage AI for trials, drug development

By Joseph Keenan

Parexel, a global CRO, will collaborate with digital pharma platform provider Partex to leverage AI to further biotech's drug discovery and development as well as streamline clinical trials.

Four years later, Ipsen's 'de-risked' rare disease drug Sohonos finally gains FDA approval

By Kevin Dunleavy

After traveling a long road full of potholes, Ipsen has finally reached its destination, gaining FDA approval for Sohonos to treat ultra-rare bone disease fibrodysplasia ossificans progressive. Ipsen called the “de-risked” when it acquired Clementia Pharmaceuticals for $1 billion back in 2019.

BlueWind Medical blows past FDA review, nabbing de novo nod for incontinence neuromod system

By Andrea Park

After getting wind of a new approach to treating overactive bladder—several years after it earned CE mark clearance in Europe—the FDA has granted the technology de novo clearance in the U.S.

With trial win, Seagen's breast cancer drug Tukysa boosts Roche's Kadcyla—and Pfizer’s $43B buyout

By Angus Liu

Pfizer is shelling out $43 billion to acquire Seagen primarily for the Seattle biotech’s antibody-drug conjugate capabilities. But a trial win for a small-molecule cancer drug makes the deal more attractive.

Cigna rolls out new digital dental screening tool to 16.5M members

By Paige Minemyer

Cigna has launched a new tool that will allow its members to use their smartphones to check for dental health issues including gum disease and cavities.

Fierce podcasts

Don’t miss an episode

'The Top Line': How left-handedness impacts brain research

This week on "The Top Line," we discuss left-handedness and its significance in neurodevelopmental and psychiatric disorder research.

'Podnosis': Email policies, and diverse investors

'The Top Line': Addressing drug shortages, plus this week's news

New Product Planning Summit

October 16-17 | Boston, MA

Examine the ways the IRA has impacted the drug pricing and access landscape and review business implications for affordability and evaluate strategies for engaging with stakeholders.

Secure your spot today and save $400 on registration. Savings end August 21st!

Resources

Whitepaper

Plan for success with your process liquid and buffer preparation

Learn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity.

Thermo Fisher Scientific Process Liquid Preparation Services

Whitepaper

Key Drivers of Sales Force Strategy in Oncology

In oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today.

Sponsored by: Blue Matter, strategic consultants in the life sciences

Whitepaper

Five ways to get the most from your lab and manufacturing facilities

Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives.

Reduce chemical lead times with just-in-time delivery

Learn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery.

Sponsored by: Thermo Fisher Scientific Production Chemicals and Services

Webinar

Novel Antibodies for the Characterization of CAR-T Cells

Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more.